Results 211 to 220 of about 40,685 (224)

Targeting Atherosclerosis: Cholesterol-Lowering Therapies with a New Immunometabolic Dress for an Old Disease. [PDF]

J Clin Med
Julve J, Rodriguez-Calvo R, Perret B, Martinez LO, Mauricio D.   +4 more
europepmc   +1 more source

Dramatic Coronary Artery Aneurysm Regression After Coronary Artery Bypass Grafting and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy. [PDF]

Interdiscip Cardiovasc Thorac Surg
Yokoyama Y, Higashino H, Fujieda H, Abe M.   +3 more
europepmc   +1 more source

Hydroxysafflor yellow A inhibits lipopolysaccharide-induced vascular smooth muscle cell-derived foam cell formation through the NLPR3/IL-1β/PCSK9 signaling pathway via activation of autophagy. [PDF]

Chin Med J (Engl)
Liu L, Li Y, Liu B, Li G, Yang C, Song J, Cui Q, Zhao J.   +7 more
europepmc   +1 more source

Differential effects of PCSK9 inhibitors and statins on plasma ceramides in coronary artery disease. [PDF]

Front Pharmacol
Zhang L, Ding Y, Zeng Y.
europepmc   +1 more source

Paradoxical LDL-C Increase after Switching from PCSK9 Inhibitors to Inclisiran: A Real-World Case Series. [PDF]

Acta Cardiol Sin
Chua SK, Hung HF, Jong BH, Chen LC.
europepmc   +1 more source

When the Target Is Not the Driver: Rethinking LDL in Cardiac Allograft Vasculopathy. [PDF]

Circulation
Truby LK, Shapiro MD.
europepmc   +1 more source

Impact of PCSK9 inhibitor on T lymphocyte subsets and cytokines in patients with acute ischemic stroke: an exploratory analysis of a randomized clinical trial. [PDF]

Front Neurol
Liu J, Han C, Ji X, Cao H, Chen S, Tan C, Hao X, Joyama Y, Zou W, Li Y, Liu J.   +10 more
europepmc   +1 more source

Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in familial hypercholesterolemia subjects. [PDF]

J Transl Med
Bosco G, Di Giacomo Barbagallo F, Di Marco M, Scilletta S, Miano N, Pistritto C, Tiralongo M, Di Stefano C, Pennisi G, De Francesco EM, Malaguarnera R, Di Pino A, Piro S, Scicali R.   +13 more
europepmc   +1 more source

<i>Proprotein Convertase Subtilisin</i>/<i>Kexin Type 9</i> (<i>PCSK9</i>) Inhibitor Therapy Reduces the Level of DNA Damage in Patients with Heterozygous Familial Hypercholesterolemia. [PDF]

Int J Mol Sci
Woźniak E, Woźniak A, Pawlos A, Broncel M, Satała J, Bukowska B, Gorzelak-Pabiś P.   +6 more
europepmc   +1 more source